Bone Regeneration from PLGA Micro-Nanoparticles.
Poly-lactic-co-glycolic acid (PLGA) is one of the most widely used synthetic polymers for development of delivery systems for drugs and therapeutic biomolecules and as component of tissue engineering applications. Its properties and versatility allow it to be a reference polymer in manufacturing of nano- and microparticles to encapsulate and deliver a wide variety of hydrophobic and hydrophilic molecules. It additionally facilitates and extends its use to encapsulate biomolecules such as proteins or nucleic acids that can be released in a controlled way. This review focuses on the use of nano/microparticles of PLGA as a delivery system of one of the most commonly used growth factors in bone tissue engineering, the bone morphogenetic protein 2 (BMP2). Thus, all the needed requirements to reach a controlled delivery of BMP2 using PLGA particles as a main component have been examined. The problems and solutions for the adequate development of this system with a great potential in cell differentiation and proliferation processes under a bone regenerative point of view are discussed.
Department of Oral Surgery and Implant Dentistry, University of Granada, 18011 Granada, Spain.
Inmaculada
I
Ortega-Oller
Department of Oral Surgery and Implant Dentistry, University of Granada, 18011 Granada, Spain.
Miguel
M
Padial-Molina
Department of Oral Surgery and Implant Dentistry, University of Granada, 18011 Granada, Spain.
Pablo
P
Galindo-Moreno
Department of Pathology, School of Medicine and IBIMER, University of Granada, 18012 Granada, Spain.
Francisco
F
O'Valle
Biocolloid and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, Spain.
Ana Belén
AB
Jódar-Reyes
Biocolloid and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, Spain ; Department of Applied Physics II, University of Málaga, 29071 Málaga, Spain.
Jose Manuel
JM
Peula-García
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry*; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage*; D001861:Bone Regeneration; D001842:Bone and Bones / Q000187:drug effects*; D002454:Cell Differentiation; D049109:Cell Proliferation; D003102:Colloids / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D020100:Hydrogels / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry; D012997:Solvents / Q000737:chemistry; D023822:Tissue Engineering / Q000379:methods; D054457:Tissue Scaffolds / Q000737:chemistry
C525718:BMP2 protein, human; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D003102:Colloids; D004337:Drug Carriers; D020100:Hydrogels; D011108:Polymers; D012997:Solvents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid